Overview A Phase 1/2 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD Status: Active, not recruiting Trial end date: 2022-05-01 Target enrollment: Participant gender: Summary This is a Phase 1/2, Open-label, Dose Escalation study to investigate SNDX-6352 in subjects with active cGVHD. Phase: Phase 1/Phase 2 Details Lead Sponsor: Syndax Pharmaceuticals